← all works
Safety and Clinical Efficacy Outcomes From the Long-term Extension Study of Tolebrutinib in Participants With Relapsing Multiple Sclerosis: 2.5-Year Results (S16.010)
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Canadian affiliationAn author listed a Canadian institution. This is the only route the usual frame has.
The three-model screen
all 1,000 screened works →All three models called this out of scope.
stratum: aff_core · design weight: 5595.24 (the sample is stratified; any rate computed without the weight is wrong)
Claude Opus 4.8OUT
genre: empirical
about Canada: no
confidence: high
Long-term extension results on safety and efficacy of tolebrutinib in relapsing multiple sclerosis; a clinical trial report.
GPT-5.6 (high)OUT
genre: empirical
about Canada: no
confidence: high
This reports long-term clinical trial safety and efficacy outcomes, not research itself.
Grok 4.5OUT
genre: empirical
about Canada: no
confidence: high
Clinical long-term safety/efficacy results for tolebrutinib in multiple sclerosis.
Abstract
To report tolebrutinib’s safety and efficacy at Week 120 (2.5 years) in a Phase 2b trial (NCT03889639) long-term safety (LTS) extension (NCT03996291).
Stored with the screening record, where it is evidence for the labels above.
The record
- Venue
- Neurology
- Topic
- Acute Lymphoblastic Leukemia research
- Field
- Medicine
- Canadian institutions
- University of TorontoSt. Michael's Hospital
- Funders
- —
- Keywords
- MedicineDiscontinuationAdverse effectExpanded Disability Status ScaleMultiple sclerosisInternal medicineUpper respiratory tract infectionPhysical therapy
- Has abstract in OpenAlex
- yes